Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy

  • Sheen, Yhun Yhong (College of Pharmacy, Ewha Womans University) ;
  • Kim, Min-Jin (College of Pharmacy, Ewha Womans University) ;
  • Park, Sang-A (College of Pharmacy, Ewha Womans University) ;
  • Park, So-Yeon (College of Pharmacy, Ewha Womans University) ;
  • Nam, Jeong-Seok (Laboratory of Tumor Suppressor, Lee Gil Ya Cancer and Diabetes Institute, Gachon University)
  • Received : 2013.09.12
  • Accepted : 2013.09.24
  • Published : 2013.09.30


TGF-${\beta}$ pathway is being extensively evaluated as a potential therapeutic target. The transforming growth factor-${\beta}$ (TGF-${\beta}$) signaling pathway has the dual role in both tumor suppression and tumor promotion. To design cancer therapeutics successfully, it is important to understand TGF-${\beta}$ related functional contexts. This review discusses the molecular mechanism of the TGF-${\beta}$ pathway and describes the different ways of tumor suppression and promotion by TGF-${\beta}$. In the last part of the review, the data on targeting TGF-${\beta}$ pathway for cancer treatment is assessed. The TGF-${\beta}$ inhibitors in pre-clinical studies, and Phase I and II clinical trials are updated.


  1. Akiyama, Y., Iwanaga, R., Saitoh, K., Shiba, K., Ushio, K., Ikeda, E., Iwama, T., Nomizu, T. and Yuasa, Y. (1997) Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 112, 33-39.
  2. Arteaga, C., Hurd, S., Winnier, A., Johnson, M., Fendly, B. and Forbes, J. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. 92, 2569-2576.
  3. Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, X., Story, B. M., Cornell, J. E., Pollock, B. H., Mundy, G. R. and Sun, L.-Z. (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-${\beta}$ type I receptor kinase inhibitor. Cancer Res. 66, 6714-6721.
  4. Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L. and Arteaga, C. L. (2007) Inhibition of TGF-${\beta}$ with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305-1313.
  5. Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S. and Troconiz, I. F. (2008) Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-${\beta}$ kinase antagonist, in mice. Eur. J. Cancer 44, 142-150.
  6. Calone, I. and Souchelnytskyi, S. (2012) Inhibition of TGFbeta signaling and its implications in anticancer treatments. Exp. Oncol. 34, 9-16.
  7. Capocasale, R. J., Lamb, R. J., Vonderheid, E. C., Fox, F. E., Rook, A. H., Nowell, P. C. and Moore, J. S. (1995) Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc. Natl. Acad. Sci. U.S.A. 92, 5501-5505.
  8. Chen, T., Yan, W., Wells, R. G., Rimm, D. L., McNiff, J., Leffell, D. and Reiss, M. (2001) Novel inactivating mutations of transforming growth factor-${\beta}$ type I receptor gene in head-and-neck cancer metastases. Int. J. Cancer 93, 653-661.
  9. Connolly, E. C., Freimuth, J. and Akhurst, R. J. (2012) Complexities of TGF-${\beta}$ targeted cancer therapy. Int. J. Biol. Sci. 8, 964-978.
  10. Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M. and Akhurst, R. J. (2011) Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term $T{\beta}RI/II$ kinase inhibition with LY2109761. Cancer Res. 71, 2339-2349.
  11. DaCosta Byfield, S. D., Major, C., Laping, N. J. and Roberts, A. B. (2004) SB-505124 is a selective inhibitor of transforming growth factor-${\beta}$ type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744-752.
  12. Datta, P. K. and Mann, J. R. (2008) Transforming growth factor-${\beta}$ (TGF-${\beta}$) signaling inhibitors cancer therapy in: Transforming Growth Factor-${\beta}$ in Cancer Therapy. In Cancer Treatment and therapy, Volume II, pp.573-587, Human Press.
  13. Derynck, R. and Akhurst, R. J. (2007) Differentiation plasticity regulated by TGF-${\beta}$ family proteins in development and disease. Nat. Cell Biol. 9, 1000-1004.
  14. Derynck, R., Akhurst, R. J. and Balmain, A. (2001) TGF-${\beta}$ signaling in tumor suppression and cancer progression. Nat. Genet. 29, 117-129.
  15. Derynck, R. and Zhang, Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF-${\beta}$ family signalling. Nature 425, 577-584.
  16. Dong, M. and Blobe, G. C. (2006) Role of transforming growth factor-${\beta}$ in hematologic malignancies. Blood 107, 4589-4596.
  17. Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y., Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H. and Shimizu, T. (2007) Ki26894, a novel transforming growth factor-${\beta}$ type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 98, 127-133.
  18. Eppert, K., Scherer, S. W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S. and Andrulis, I. L. (1996). MADR2 maps to 18q21 and encodes a $TGF{\beta}$-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543-552.
  19. Fernandez, T., Amoroso, S., Sharpe, S., Jones, G. M., Bliskovski, V., Kovalchuk, A., Wakefi eld, L. M., Kim, S.-J., Potter, M. and Letterio, J. J. (2002) Disruption of transforming growth factor ${\beta}$ signaling by a novel ligand-dependent mechanism. J. Exp. Med. 195, 1247-1255.
  20. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. and Licona-Limón, P. (2010). The polarization of immune cells in the tumour environment by $TGF{\beta}$. Nat. Rev. Immunol. 10, 554-567.
  21. Ganapathy, V., Ge, R., Grazioli, A., Xie, W., Banach-Petrosky, W., Kang, Y., Lonning, S., McPherson, J., Yingling, J. M. and Biswas, S. (2010) Targeting the transforming growth factor-${\beta}$ pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9, 122.
  22. Goggins, M., Shekher, M., Turnacioglu, K., Yeo, C. J., Hruban, R. H. and Kern, S. E. (1998) Genetic alterations of the transforming growth factor ${\beta}$ receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58, 5329-5332.
  23. Gordon, M. S., Ilaria, R. Jr., de Alwis, D. P., Mendelson, D. S., McKane, S., Wagner, M. M., Look, K. Y. and LoRusso, P. M. (2013) A Phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 21-27.
  24. Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., Neumann, A., Brattain, M. G., Chang, J. and Kim, S.-J. (1999) Mutational inactivation of transforming growth factor ${\beta}$ receptor type II in microsatellite stable colon cancers. Cancer Res. 59, 320-324.
  25. Grady, W. M., Rajput, A., Myeroff, L., Liu, D. F., Kwon, K., Willis, J. and Markowitz, S. (1998) Mutation of the type II transforming growth factor-${\beta}$ receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 58, 3101-3104.
  26. Hagedorn, H. G., Bachmeier, B. E. and Nerlich, A. G. (2001) Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-${\beta}$ in invasive carcinomas (Review). Int. J. Oncol. 18, 669-681.
  27. Hau, P., Jachimczak, P., Schlingensiepen, R., Schulmeyer, F., Jauch, T., Steinbrecher, A., Brawanski, A., Proescholdt, M., Schlaier, J. and Buchroithner, J. (2007) Inhibition of TGF-${\beta}$ 2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17, 201-212.
  28. Heldin, C.-H., Miyazono, K. and Ten Dijke, P. (1997) TGF-${\beta}$ signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
  29. Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F. and Rich, J. N. (2004) SB-431542, a small molecule transforming growth factor-${\beta}$-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737-745.
  30. Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., Manova-Todorova, K., Blasberg, R., Gerald, W. L. and Massague, J. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 102, 13909-13914.
  31. Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Corden- Cardo, C., Guise, T. A. and Massague, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549.
  32. Kim, D.-K., Sheen, Y. Y., Jin, C., Park, C.-Y., Domalapally, S., Kota, S. R., Maddeboina, K. and Bala, S. V. (2011) 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors. Google Patents. PCT/KR2011/004631.
  33. Kingsley, D. M. (1994) The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8, 133-146.
  34. Kingsley, L. A., Fournier, P. G., Chirgwin, J. M. and Guise, T. A. (2007) Molecular biology of bone metastasis. Mol. Cancer Ther. 6, 2609-2617.
  35. Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A. and Kang, Y. (2009) Imaging transforming growth factor-${\beta}$ signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960-966.
  36. Lampropoulos, P., Zizi-Sermpetzoglou, A., Rizos, S., Kostakis, A., Nikiteas, N. and Papavassiliou, A. G. (2012) TGF-beta signalling in colon carcinogenesis. Cancer Lett. 314, 1-7.
  37. Lee, G. Y., Kenny, P. A., Lee, E. H. and Bissell, M. J. (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 4, 359-365.
  38. Levy, L. and Hill, C. S. (2006) Alterations in components of the TGF-${\beta}$ superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41-58.
  39. Lindley, L. E. and Briegel, K. J. (2010) Molecular characterization of $TGF{\beta}$-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells. Biochem. Biophys. Res. Commun. 399, 659-664.
  40. Maliekal, T. T., Antony, M.-L., Nair, A., Paulmurugan, R. and Karunagaran, D. (2003) Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 22, 4889-4897.
  41. Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C. and Shipitsin, M. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
  42. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W. and Vogelstein, B. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338.
  43. Massague, J. (2000) How cells read TGF-${\beta}$ signals. Nat. Rev. Mol. Cell Biol. 1, 169-178.
  44. Massague, J. (2008) $TGF{\beta}$ in cancer. Cell 134, 215-230.
  45. Massague, J. and Gomis, R. R. (2006) The logic of $TGF{\beta}$ signaling. FEBS Lett. 580, 2811-2820.
  46. Matsuyama, S., Iwadate, M., Kondo, M., Saitoh, M., Hanyu, A., Shimizu, K., Aburatani, H., Mishima, H. K., Imamura, T. and Miyazono, K. (2003) SB-431542 and Gleevec inhibit transforming growth factor-${\beta}$-induced proliferation of human osteosarcoma cells. Cancer Res. 63, 7791-7798.
  47. Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L. and Chiao, P. J. (2008) LY2109761, a novel transforming growth factor ${\beta}$ receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840.
  48. Meulmeester, E. and ten Dijke, P. (2011). The dynamic roles of TGF-${\beta}$ in cancer. J. Pathol. 223, 205-218.
  49. Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Barón, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A. and Welm, A. L. (2009) The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-${\beta}$ signaling. J. Clin.Invest. 119, 2678-2690.
  50. Micalizzi, D. S., Wang, C.-A., Farabaugh, S. M., Schiemann, W. P. and Ford, H. L. (2010) Homeoprotein Six1 increases TGF-${\beta}$ Type I receptor and converts TGF-${\beta}$ signaling from suppressive to supportive for tumor growth. Cancer Res. 70, 10371-10380.
  51. Mishra, L., Derynck, R. and Mishra, B. (2005) Transforming growth factor-${\beta}$ signaling in stem cells and cancer. Science 310, 68-71.
  52. Mohammad, K. S., Javelaud, D., Fournier, P. G., Niewolna, M., McKenna, C. R., Peng, X. H., Duong, V., Dunn, L. K., Mauviel, A. and Guise, T. A. (2011) TGF-${\beta}$-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71, 175-184.
  53. Moon, J., Kim, H., Cho, I., Sheen, Y. and Kim, D. (2006) IN-1130, a novel transforming growth factor-${\beta}$ type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70, 1234-1243.
  54. Muraoka-Cook, R. S., Dumont, N. and Arteaga, C. L. (2005) Dual role of transforming growth factor ${\beta}$ in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 11, 937s-943s.
  55. Muraoka, R. S., Dumont, N., Ritter, C. A., Dugger, T. C., Brantley, D. M., Chen, J., Easterly, E., Roebuck, L. R., Ryan, S. and Gotwals, P. J. (2002) Blockade of TGF-${\beta}$ inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559.
  56. Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H. and Anver, M. R. (2008) An anti-transforming growth factor ${\beta}$ antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835-3843.
  57. Padua, D. and Massague, J. (2009) Roles of $TGF{\beta}$ in metastasis. Cell Res. 19, 89-102.
  58. Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R. and Massague, J. (2008) $TGF{\beta}$ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77.
  59. Park, C.-Y., Son, J.-Y., Jin, C. H., Nam, J.-S., Kim, D.-K. and Sheen, Y. Y. (2011a) EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur. J. Cancer 47, 2642-2653.
  60. Park, C. Y., Kim, D. K. and Sheen, Y. Y. (2011b) EW-7203, a novel small molecule inhibitor of transforming growth factor-${\beta}$ (TGF-${\beta}$) type I receptor/activin receptor/like kinase-5, blocks TGF-${\beta}1$- mediated epithelial-to-mesenchymal transition in mammary epithelial cells. Cancer Sci. 102, 1889-1896.
  61. Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W. and Vogelstein, B. (1995) Microsatellite instability and mutations of the transforming growth factor ${\beta}$ type II receptor gene in colorectal cancer. Cancer Res. 55, 5548-5550.
  62. Peng, H., Carretero, O. A., Vuljaj, N., Liao, T.-D., Motivala, A., Peterson, E. L. and Rhaleb, N.-E. (2005) Angiotensin-converting enzyme inhibitors a new mechanism of action. Circulation 112, 2436-2445.
  63. Porter, P. L. (2009) Global trends in breast cancer incidence and mortality. Salud Publica Mex. 51, s141-s146.
  64. Roberts, A. B. and Wakefield, L. M. (2003) The two faces of transforming growth factor ${\beta}$ in carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 100, 8621-8623.
  65. Rowland-Goldsmith, M. A., Maruyama, H., Matsuda, K., Idezawa, T., Ralli, M., Ralli, S. and Korc, M. (2002) Soluble type II transforming growth factor-${\beta}$ receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis1. Mol. Cancer Ther. 1, 161-167.
  66. Sanchez-Elsner, T., Botella, L. M., Velasco, B., Corbi, A., Attisano, L. and Bernabeu, C. (2001) Synergistic cooperation between hypoxia and transforming growth factor-${\beta}$ pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 276, 38527-38535.
  67. Sanchez-Zamorano, L. M., Flores-Luna, L., Angeles-Llerenas, A., Romieu, I., Lazcano-Ponce, E., Miranda-Hernandez, H., Mainero-Ratchelous, F. and Torres-Mejía, G. (2011) Healthy lifestyle on the risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 912-922.
  68. Sawyer, T. K. (2004) Novel oncogenic protein kinase inhibitors for cancer therapy. Curr. Med. Chem. Anticancer Agents 4, 449-455.
  69. Schlingensiepen, K. H., Jaschinski, F., Lang, S. A., Moser, C., Geissler, E. K., Schlitt, H. J., Kielmanowicz, M. and Schneider, A. (2011) Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 102, 1193-1200.
  70. Shi, Y. and Massague, J. (2003) Mechanisms of TGF-${\beta}$ signaling from cell membrane to the nucleus. Cell 113, 685-700.
  71. Shinto, O., Yashiro, M., Kawajiri, H., Shimizu, K., Shimizu, T., Miwa, A. and Hirakawa, K. (2010) Inhibitory effect of a $TGF\beta$ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br. J. Cancer 102, 844-851.
  72. Shirakihara, T., Horiguchi, K., Miyazawa, K., Ehata, S., Shibata, T., Morita, I., Miyazono, K. and Saitoh, M. (2011) TGF-${\beta}$ regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J. 30, 783-795.
  73. Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S. and Reiss, M. (2004) Targeting endogenous transforming growth factor ${\beta}$ receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype 1. Cancer Res. 64, 5200-5211.
  74. Takenoshita, S., Tani, M., Nagashima, M., Hagiwara, K., Bennett, W. P., Yokota, J. and Harris, C. C. (1997) Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 14, 1255-1258.
  75. Takeuchi, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Kido, S., Harada, T., Tanaka, O., Miki, H. and Nakamura, S. (2010) TGF-${\beta}$ inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 5, e9870.
  76. Tanaka, H., Shinto, O., Yashiro, M., Yamazoe, S., Iwauchi, T., Muguruma, K., Kubo, N., Ohira, M. and Hirakawa, K. (2010) Transforming growth factor ${\beta}$ signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep. 24, 1637-1643.
  77. Thiery, J. P., Acloque, H., Huang, R. Y. and Nieto, M. A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
  78. Thomas, D. A. and Massagué, J. (2005) TGF-${\beta}$ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380.
  79. Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H. and Moustakas, A. (2006) Transforming growth factor-${\beta}$ employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol. 174, 175-183.
  80. Travis, R. C., Reeves, G. K., Green, J., Bull, D., Tipper, S. J., Baker, K., Beral, V., Peto, R., Bell, J. and Zelenika, D. (2010) Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study. Lancet 375, 2143-2151.
  81. Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M. and Herrlinger, U. (2004) SD-208, a novel transforming growth factor ${\beta}$ receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954-7961.
  82. van Meeteren, L. A., Thorikay, M., Bergqvist, S., Pardali, E., Stampino, C. G., Hu-Lowe, D., Goumans, M.-J. and ten Dijke, P. (2012) Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J. Biol. Chem. 287, 18551-18561.
  83. Viloria-Petit, A. M., David, L., Jia, J. Y., Erdemir, T., Bane, A. L., Pinnaduwage, D., Roncari, L., Narimatsu, M., Bose, R. and Moffat, J. (2009) A role for the $TGF{\beta}$-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 106, 14028-14033.
  84. Wakefield, L. M. and Roberts, A. B. (2002) TGF-${\beta}$ signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29.
  85. Wang, D., Kanuma, T., Mizunuma, H., Takama, F., Ibuki, Y., Wake, N., Mogi, A., Shitara, Y. and Takenoshita, S. (2000) Analysis of specific gene mutations in the transforming growth factor-${\beta}$ signal transduction pathway in human ovarian cancer. Cancer Res. 60, 4507-4512.
  86. Wendt, M. K., Smith, J. A. and Schiemann, W. P. (2010) Transforming growth factor-${\beta}$-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29, 6485-6498.
  87. Wiercinska, E., Naber, H. P., Pardali, E., van der Pluijm, G., van Dam, H. and ten Dijke, P. (2011) The TGF-${\beta}$/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res. Treat. 128, 657-666.
  88. Yakicier, M., Irmak, M., Romano, A., Kew, M. and Ozturk, M. (1999) Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18, 4879-4883.
  89. Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., Mac-Gregor, J., Patel, S. C., Khozin, S., Liu, Z.-y. and Green, J. (2002) Lifetime exposure to a soluble TGF-${\beta}$ antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615.
  90. Yingling, J. M., Blanchard, K. L. and Sawyer, J. S. (2004) Development of TGF-${\beta}$ signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 3, 1011-1022.
  91. Zhang, B., Halder, S. K., Zhang, S. and Datta, P. K. (2009) Targeting transforming growth factor-${\beta}$ signaling in liver metastasis of colon cancer. Cancer Lett. 277, 114-120.
  92. Zhang, Y. and Derynck, R. (1999) Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol. 9, 274-279.

Cited by

  1. The Effect of (1S,2S,3E,7E,11E)-3,7,11,15-Cembratetraen-17,2-Olide (LS-1) from Lobophyyum sp. on the Apoptosis Induction of SNU-C5 Human Colorectal Cancer Cells vol.24, pp.6, 2016,
  2. Epithelial to Mesenchymal Transition in a Clinical Perspective vol.2015, 2015,
  3. Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression vol.23, pp.2, 2015,
  4. Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-β1 in node-positive tissue vol.13, pp.6, 2016,
  5. The Anticancer Effect of (1S,2S,3E,7E,11E)-3,7,11, 15-Cembratetraen-17,2-olide(LS-1) through the Activation of TGF-β Signaling in SNU-C5/5-FU, Fluorouracil-Resistant Human Colon Cancer Cells vol.13, pp.3, 2015,
  6. Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches vol.7, 2016,
  7. Excessive activation of the TLR9/TGF-β1/PDGF-B pathway in the peripheral blood of patients with systemic lupus erythematosus vol.19, pp.1, 2017,
  8. TGFβ and IL10 have an impact on risk group and prognosis in childhood ALL vol.62, pp.1, 2015,
  9. Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition vol.22, pp.11, 2015,
  10. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer vol.27, pp.7, 2017,
  11. The role of endoglin in kidney fibrosis vol.16, 2014,
  12. The emerging role of RUNX3 in cancer metastasis (Review) vol.35, pp.3, 2016,
  13. Cancer stem cells and HER2 positive breast cancer: The story so far vol.3, pp.2, 2016,
  14. TGF-ß alterations in oral squamous cell carcinoma. Narrative review vol.5, pp.5, 2016,
  15. Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy vol.370, pp.1, 2017,
  16. Metformin is a novel suppressor for transforming growth factor (TGF)-β1 vol.6, pp.1, 2016,
  17. Regulated intramembrane proteolysis of the TGFβ type I receptor conveys oncogenic signals vol.10, pp.11, 2014,
  18. Intertwining of Activin A and TGFβ Signaling: Dual Roles in Cancer Progression and Cancer Cell Invasion vol.7, pp.1, 2014,
  19. Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition vol.136, pp.6, 2015,
  20. Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects vol.38, pp.8, 2015,
  21. Switching Roles of TGF-β in Cancer Development: Implications for Therapeutic Target and Biomarker Studies vol.5, pp.12, 2016,
  22. Two Faces of TGF-Beta1 in Breast Cancer vol.2014, 2014,
  23. The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells vol.407, 2015,
  24. LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer vol.10, pp.8, 2018,
  25. Secretomes reveal several novel proteins as well as TGF-β1 as the top upstream regulator of metastatic process in breast cancer vol.170, pp.2, 2018,
  26. Current status and future prospects of transforming growth factor-β as a potential prognostic and therapeutic target in the treatment of breast cancer vol.120, pp.5, 2019,